Rischin D, Hansen AR, Cohen EEW, Tahara M, et al. INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Clin Cancer Res 2025 Dec 22. doi: 10.1158/1078-0432.CCR-25-1197.
PMID: 41427951